Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154238 | 0.79 | KMT2A (0.50) | KMT2AMEN1RAB9ACA2CYP2C9 | |
| SCHEMBL22623631 | 0.67 | CYP2C9 (0.41) | KMT2AMEN1RAB9ACYP2C9BLM | |
| SCHEMBL30457291 | 0.64 | LMNA (0.53) | KMT2AMEN1RAB9ACYP2C9BLM | |
| SCHEMBL22623629 | 0.63 | CA2 (0.51) | KMT2AMEN1RAB9ACA2CYP2C9 | |
| Thiophenytoin SCHEMBL1685397 | 0.61 | CYP2C9 (0.64) | KMT2AMEN1CYP2C9BLMPMP22 | |
| SCHEMBL7236829 | 0.60 | ALDH1A1 (0.45) | KMT2AMEN1CA2CYP2C9BLM | |
| SCHEMBL7977554 | 0.60 | ALDH1A1 (0.45) | KMT2AMEN1CA2CYP2C9BLM | |
| SCHEMBL13923610 | 0.60 | HTR2A (0.34) | KMT2AMEN1CA2HTR2ANAT1 | |
| SCHEMBL4697905 | 0.59 | CYP2C9 (0.41) | KMT2AMEN1CYP2C9BLMPMP22 | |
| SCHEMBL598851 | 0.59 | MAPT (0.41) | KMT2AMEN1RAB9ACYP2C9BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-5804411-A | KEY PROTEIN IN THE SIGNAL TRANSMISSION OF INSULIN; USEFUL IN THE PREVENTION AND/OR TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5506205-A | TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0659883-A2 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | KMT2A 3844/4885MEN1 2345/4885RAB9A 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.